Last update Aug. 30, 2018
An opioid, synthetic derivative of pethidine with little or no analgesic effect. It acts by decreasing intestinal motility and with it the frequency and fluidity of bowel movements.
Used orally every 6 hours for the symptomatic treatment of acute diarrhea.
Since the last update we did not found published data on its excretion in breastmilk.
Although the manufacturer warns that its active metabolite could be excreted in breastmilk (Pfizer 2017), several expert authors believe that excretion in breastmilk is minimal (Hale 2017 p289, Chen 2010).
In order to prevent its abuse it is often associated with atropine, which could affect breastfed children (Gattuso 1994). However, the American Academy of Pediatrics classifies atropine as compatible with breastfeeding (AAP 2001).
Its indiscriminate use in gastroenteritis is not justifiable. Most gastroenteritis does not require medication: good hydration and maintaining a normal diet is sufficient.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM